Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Relapsed Osteosarcoma and Ewing Sarcoma
NCT02243605Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2014
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in osteosarcoma (OS), Ewing sarcoma, sponsored by National Cancer Institute. Started Dec 2014; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on NCT02243605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243605.